FDA revise guidelines for rheumatoid arthritis drug Leflunomide
The Food and Drug Administration (FDA) in the United States has issued a safety update for a drug used to treat active rheumatoid arthritis. They now recommend that all patients must be screened for tuberculosis and other pulmonary infections such as aspergillosis prior to taking Leflunomide due to the risk that the drug will increase the chances that these infections will get worse.Medications
0 Response to "FDA revise guidelines for rheumatoid arthritis drug Leflunomide"
Post a Comment